Transaktionen anzeigen
Private Equity | Gesundheitswesen

Probiomed has been acquired by Sanfer

The shareholders of Probiomed S.A. de C.V. have sold the company to Laboratorios Sanfer.

Probiomed was founded in 1970 and is a vertically integrated developer, manufacturer and marketer of pharmaceutical and biopharmaceutical products. The company has three production plants and one of the most advanced R&D platforms in the region. The R&D team has 46 engineers who have developed and launched over 120 products, 14 of which were biopharmaceuticals.

Sanfer, with over 80 years of history, is one of the leading companies in the Mexican pharmaceutical market. It participates in more than 10 therapeutic areas, including infectiology, algology, cardiology, gastroenterology, central nervous system, metabolic syndrome, gynecology, urology, oncology, over-the-counter products and animal health products for all types of species.

Oaklins’ team in Mexico acted as the financial advisor to Probiomed in the debt restructuring of US$120 million under Chapter 11 “Concurso Mercantil” in Mexico, as well as in the structuring of the acquisition by Sanfer, resulting in an equity injection of US$30 million.

DIENSTLEISTUNG
PARTEIEN

Sprechen Sie mit dem Deal Team

Andrei Lepiavka

Managing Partner
Mexico City, Mexiko
Oaklins Mexico

Arseny Lepiavka

Managing Partner
Mexico City, Mexiko
Oaklins Mexico

Transaktionen

Valmiermuižas Alus has been acquired by Cēsu Alus
Private Equity | Lebensmittel- und Getränkeindustrie

Valmiermuižas Alus has been acquired by Cēsu Alus

Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.

Mehr erfahren
Die Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland
Gesundheitswesen

Die Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland

Die LabPoint Medizinische Laboratorien AG wurde von Affidea Switzerland AG übernommen. Mit Affidea hat die Lindenhofgruppe AG einen starken strategischen Partner für die Weiterentwicklung der LabPoint gewonnen. Die Lindenhofgruppe bleibt bedeutende Aktionärin und Grosskundin des Unternehmens. Damit schafft sie die Grundlage für eine nachhaltige Weiterentwicklung von LabPoint unter einer neuen Ankeraktionärin. LabPoint soll ihre Position in der Labordiagnostik weiter stärken und gezielt ausbauen.

Mehr erfahren
Armira has signed an agreement to acquire a majority stake in Viabus
Private Equity | Handel

Armira has signed an agreement to acquire a majority stake in Viabus

Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.

Mehr erfahren